130 results about "Atrophy" patented technology

The invention relates to the technical field of artificial intelligence, and provides a gastric cancer risk quantitative scoring method, system and equipment based on artificial intelligence, and the method comprises the steps: recognizing the image type of each image frame in alimentary canal endoscope image data; for the electronic dyeing image frame, identifying a part contour region and an intestinal contour region of the feature part in the image frame, determining an intestinal epithelial metaplasia grading category of the feature part according to an area proportion of the intestinal contour region in the part contour region, and performing electronic dyeing intestinal scoring on the image data; for the white light image frame, gastroscope part types included in the image frame and focus area types of all gastroscope parts are recognized; performing atrophy scoring on the image data according to the position distribution of the focus area of the atrophy type; performing table state scoring on the image data according to whether the plica enlargement, nodular gastritis and diffuse redness focus areas exist or not; and realizing gastric cancer risk quantitative scoring according to the electronic staining intestinal scoring, the atrophy scoring and the epistatic state scoring.

The invention discloses a multi-modal feature fusion prediction method and system for early screening of Alzheimer's disease, and belongs to the technical field of brain disease prediction. The method comprises the following steps: acquiring multi-dimensional data containing cognitive test scores, brain image scanning results and biomarker concentration levels from a patient record database, and performing standardization processing to obtain a multi-dimensional data set in a unified format; key feature vectors are extracted through a dimensionality reduction analysis method to capture the covariant relation between cognitive test scores and brain image changes; when the reduction range of the cognitive test score exceeds a preset threshold value and the brain image displays an atrophy sign, a classification model is constructed through an integrated learning method to preliminarily classify abnormal signals; and fusing the biomarker concentration level to obtain an abnormal signal vector. According to the method, the accuracy and efficiency of early screening of brain diseases such as Alzheimer's disease are remarkably improved through accurate evaluation of key parts of the human brain, such as hippocampus.

The present invention relates to a compound of formula (I) wherein R1 is a hydrogen atom, halogen or -(C1-C2)alkyl, R2 is -halo(C1-C2)alkoxy, and R3 and R4 form together with N to which they are attached an optionally substituted 5-7 membered monocyclic heterocycloalkyl ring or an optionally substituted 8-11 membered bicyclic heterocycloalkyl ring. The present invention also relates to a medicament and a pharmaceutical composition comprising said compound of formula (I), as well as their therapeutic uses, in particular as inhibitor of NOD-like receptor protein 3 inflammasome for preventing and / or treating Parkinson's disease, frontotemporal Dementia, Multiple System Atrophy, Alzheimer's disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis or brain injury.

The present invention relates to a system and method configured for analysing acoustic parameters of speech to detect, diagnose, predict and / or monitor progression of a condition, disorder, or disease, and more particularly, any of paediatric and adult neurological and central nervous system conditions including but not limited to low back pain, multiple sclerosis, stroke, seizures, Alzheimer's disease, Parkinson's disease, dementia, motor neuron disease, muscular atrophy, acquired brain injury, cancers involving neurological deficits, paediatric developmental conditions and rare genetic disorders such as spinal muscular atrophy. The system and method extracts a first formant data set from words spoken by an individual and uses these to classify the vowels in the words on a first computing device, such as a mobile smart phone equipped with a microphone into which an individual speaks. The system stores at least some of these frequencies for the vowel formants in a second formant data set as a recorded file and provides the second formant data set as input to acoustic metrics to generate score data from which an assessment is made to determine the articulation level of the vowels in the words spoken by the individual, allowing allow for detection, diagnosis, prediction and / or monitoring progression of the condition, disorder, or disease.

The application belongs to the technical field of medical image processing and diagnosis, and particularly relates to an improved RCN-based alopecia typing and grading intelligent identification method and system, wherein alopecia image data is acquired, a U-Net++ model is trained, hair probability distribution is obtained, a hair mask is generated, an alopecia region is segmented, and continuous frame images are generated through SIFT feature matching and affine transformation; spatiotemporal joint features are extracted by using an improved RCN network, combined with a ResNet-50 backbone network, to generate alopecia local feature maps, spatiotemporal self-attention encoders and double-path attention architectures are fused, through a dynamic weight distribution mechanism, key hair growth regions are located and hair growth directions are analyzed, and density change trends are obtained; through an ensemble learning model, alopecia density and grade are identified, health is scored, and a heat map is generated to label hair follicle atrophy regions. Thus, the problems of weak feature expression ability, poor scene adaptability and insufficient positioning accuracy in the prior art are solved.

The utility model relates to a temporal muscle suturing and fixing device for neurosurgery, which is characterized in that at least one suturing line is connected onto a screw, and the other end of each suturing line is connected with a suturing needle. The device has the beneficial effects that the screw is directly fixed on the skull; the needle holder is provided with a suture needle to suture temporalis, and the suture needle is removed; the thread on one side of the screw and the thread on the other side of the temporalis can be knotted, fixation after the temporalis is cut open in a neurosurgery operation can be effectively completed, poor fixation of the temporalis is avoided, temporalis atrophy of a patient after an operation is avoided, psychological stress brought to the patient due to unattractive appearance caused by amyotrophy on one side after the operation is avoided, the design is simple and practical, and practicability is high. The device can be popularized to be used in various intracranial operations.

The invention provides a senile dementia early diagnosis method based on hippocampus magnetic resonance imaging, which comprises the following steps that: according to a segmented image, a contour extraction algorithm is adopted to obtain multi-layer two-dimensional contour data to obtain a contour sequence, and the contour extraction algorithm carries out gradient analysis and threshold filtering on geometric features of a hippocampus, and captures boundary details; the contour sequence is subjected to space alignment processing, an alignment contour set is obtained, displacement deviation between different layers is eliminated through a transformation correction method in the space alignment processing, and the alignment contour set is generated; calculating volume and morphological indexes according to the preliminary three-dimensional model, and determining the atrophy degree; and comparing the refined three-dimensional structure with a preset reference model to generate difference mapping, judging the diagnosis precision, and adopting a geometric feature deviation measurement method to evaluate the structural difference in comparison to generate the difference mapping. According to the method, the fidelity and diagnosis precision of three-dimensional reconstruction of the hippocampus are remarkably improved, and reliable technical support is provided for early diagnosis of neurodegenerative diseases.

The present invention relates to novel molecules that can be employed for the prevention, alleviation, treatment and / or diagnosis of diseases, disorders and abnormalities associated with alpha-synuclein (α-synuclein, A-synuclein, aSynuclein, A-syn, α-syn, aSyn, a-syn) aggregates, including, but not limited to, Lewy bodies and / or Lewy neurites, such as Parkinson's disease, Multiple System Atrophy, Lewy Body dementia (LBD; dementia with Lewy bodies (DLB) (“pure” Lewy body dementia), Parkinson's disease dementia (PDD)) or Diffuse Lewy Body Disease. The invention relates to alpha-synuclein binding molecules, in particular to alpha-synuclein antibodies or an antigen-binding fragment or a derivative thereof and uses thereof. The present molecules can also be used for determining a predisposition to such a disorder, disease or abnormality, monitoring residual disorder, disease or abnormality, or predicting the responsiveness of a patient who is suffering from such a disorder, disease or abnormality to treatment with a certain medicament.

Disclosed is a method of treating a neurodegenerative disease such as Parkinson's disease, diffuse Lewy body disease, transitional Lewy body dementia, and multiple system atrophy in a subject. The method comprises administering to the subject a therapeutically effective amount of a peptide comprising an α-synuclein binding domain operably linked to a protein transduction domain and a proteasomal targeting domain, wherein the α-synuclein binding domain is derived from a reversed sequence of β-synuclein. Other methods, as well as uses and compositions, are disclosed.

The invention discloses a leg rehabilitation training device, and particularly relates to the technical field of medical instruments.The leg rehabilitation training device comprises a supporting assembly, a fixing assembly is installed on the upper portion of the supporting assembly, a cavity is formed in the right portion of the fixing assembly, an adjusting assembly is installed in the cavity, and a driving assembly is installed in an inner cavity of the fixing assembly; a training assembly is installed in an inner cavity of the fixing assembly. According to the leg rehabilitation training device, a patient does not need to get out of the bed by himself or herself through the designed adjusting assembly, the patient can be gradually transited from a lying state to a standing state by adjusting the stable angle of the turnover bed, and the safety risks such as falling and collision caused by lower limb weakness and lack of balance feeling in the whole process are avoided; meanwhile, by simulating the standing state, leg muscles can naturally bear the body weight, core muscle groups such as quadriceps femoris muscles and gastrocnemius muscles can be activated, muscle loss atrophy caused by long-term bed lying can be prevented, bone metabolism can be stimulated through load bearing, and the occurrence risk of osteoporosis can be reduced.

The invention relates to the technical field of medical auxiliary diagnosis, and particularly discloses an auxiliary diagnosis method for multifocal motor neuropathy and peingshan disease, which comprises the following steps: step S100: performing electromyogram detection, serological examination and muscle biopsy on an examined object to obtain electromyogram signal data, serological examination result data and muscle biopsy result data; s200, performing feature extraction on the electromyogram signal data, the serological examination result data and the muscle biopsy result data, and combining the extracted features to form a feature vector; step S300, obtaining output classification probabilities, wherein the classification probabilities correspond to the multi-focus motor neuropathy and the Pingshan disease, and excluding three categories of the multi-focus motor neuropathy and the Pingshan disease; electromyogram signals, serological examination and muscle biopsy multi-source data are fused to extract core features, a classification model is constructed by using a random forest or XGBoost algorithm, and the automation and standard unification of the whole diagnosis process are realized.

The utility model discloses an oral implant which comprises a bone surface supporting structure, the appearance of the bone surface supporting structure is attached to an upper jaw alveolar bone surface or a lower jaw alveolar bone surface, and a net-shaped through hole is formed in the bone surface supporting structure and corresponds to the alveolar bone surface; a plurality of base tables protruding out of the surface are arranged on the surface of one side of the bone surface supporting structure, and the base tables are used for fixedly connecting the oral implant with a prosthesis; one end, connected to the bone surface supporting structure, of the abutment is provided with an intraosseous implant implanted into the jaw bone. According to the utility model, the traditional subperiosteal implant is improved, the subperiosteal implant is designed in the area with insufficient bone mass of the jaw bone, and the novel stent-shaped implant is formed by combining the subperiosteal implant with the intraosseous implant in the area with sufficient bone mass of the jaw bone, so that independent bone increment operation is not needed, and the implant can be implanted only by one operation; and the clinical problem that a patient with serious atrophy of the alveolar ridge is difficult to implant and repair is effectively solved.

The present application belongs to the technical field of traditional Chinese medicine composition, and relates to a traditional Chinese medicine transdermal external preparation for treating vulvar hypopigmentation disease. The preparation is a paste prepared by mixing traditional Chinese medicine powder and horse oil. The traditional Chinese medicine powder is composed of the following raw materials by weight: Xuchangqing 10-12, Pugongying 10-15, Difusiduo 12-15, Tuzifuding 12-15, Baiji 10-15, Huzhang 9-12, Quansie 6-10, Diyu 10-12, Xuezhi 10-12, Danggui 6-10, Rushang 6-10, Miedu 6-10, Bingpian 1-3. The traditional Chinese medicine transdermal external preparation has definite and significant effects on vulvar hypopigmentation disease, especially in relieving intractable pruritus, promoting pigment recovery and improving skin sclerosis / atrophy. The traditional Chinese medicine transdermal external preparation has high safety, few adverse reactions and low recurrence rate.

The invention discloses a lower limb traction massage device for assisting knee joint stiffness treatment. The lower limb traction massage device comprises a main supporting plate, a traction supporting plate, a massage assembly installed on the traction supporting plate, an application mechanism in a leg limiting sleeve and a telescopic pipe connected with a steam heating mechanism and the application mechanism. The supporting plate is provided with a supporting table with a steam heating mechanism; the traction supporting plate is hinged to the main supporting plate, and the traction supporting plate is provided with a leg limiting sleeve and a traction assembly. The massage assembly is used for massage, and the atrophy phenomenon caused by knee joint stiffness is effectively avoided; the traction assembly is matched with the traction supporting plate, so that muscles at knee joints are relaxed; the steam heating mechanism and the dressing mechanism are matched to perform constant-temperature application treatment on the knee joint, so that the application time is effectively shortened, and the problem of skin allergy of a patient due to long application time of the dressing is solved; the device replaces part of work of medical staff, the situation that the massage effect is affected by the skill degree can be avoided, and the labor intensity of the medical staff can be relieved.

The present disclosure relates to a composite material for application to a bone defect site to promote new bone growth at the site comprising: a combination of freeze-dried mineralized bone allograft particles; and a monophasic gel comprising cross-linked hyaluronic acid; wherein the hyaluronic acid is cross-linked by a cross-linking agent, the cross-linking agent being a diglycidyl ether. The present disclosure also relates to a method to obtain a composite material for application to a bone defect site to promote new bone growth at the site comprising mixing freeze-dried mineralized bone allograft particles with a monophasic gel comprising hyaluronic acid; and to a bone regenerative material comprising the composite material as defined herein for use in a method of treating a patient suffering from a degenerative bone condition, bone loss, bone deficiency or bone atrophy.

Provided is a recombinant adeno-associated viral (rAAV) vector comprising one or two of (a) to (c): (a) a nucleotide sequence encoding aromatic L-amino acid decarboxylase (AADC), (b) a nucleotide sequence encoding glucocerebrosidase (GBA1); and (c) a nucleotide sequence encoding a neurotrophic factor (NTF), such as cerebral dopamine neurotrophic factor (CDNF) or glial cell derived neurotrophic factor (GDNF), for treating neurodegenerative disorders, particularly Parkinson's disease (PD), Multiple system atrophy (MSA), Gaucher's disease (GD), and other proteinopathies. Also provided herein are viral particles comprising the rAAV vector, a pharmaceutical composition comprising the viral particles, and uses thereof.

The present disclosure relates to a compound of formula (I) which is in crystalline Form 1, characterized by having a powder X-ray diffractogram displaying peaks expressed as degree 2-Theta angles at about 3.3, 10.0, 20.1, 21.7, and 25.0. The present disclosure also relates to processes for its preparation, as well as a medicament and a pharmaceutical composition comprising it. The present disclosure further concerns the crystalline Form 1 of compound of formula (I) for use as a medicine and more particularly in the prevention and / or in the treatment of Parkinson's disease, frontotemporal dementia, multiple system atrophy, Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, or brain injury.

The invention belongs to the technical field of biological medicines, and particularly relates to application of miR-206-3p in regulation and control of skeletal muscle atrophy, and the change condition of the miR-206-3p level is measured by constructing an in-vitro cancer cachexia myotubular atrophy model; it is verified that in-vitro addition of miR-206-3p mimics relieves in-vitro myotube atrophy induced by a cancer conditioned culture medium, inhibits expression of a myotube marker gene and inhibits proteolysis and metabolism pathways and cell apoptosis of myotubes, so that myotube atrophy induced by cancer cachexia is inhibited. The invention opens up a new thought for the research of cachexia pathogenesis, and also provides a potential new target for the research and development of cachexia treatment and / or cachexia prevention drugs.

The invention discloses a rehabilitation medical bed for assisting lower limb rehabilitation and relates to the technical field of medical beds, the rehabilitation medical bed comprises a bed plate and a bottom plate, supporting frames are arranged on the two sides of the bottom of the bed plate, the bottom plate is arranged at the bottoms of the supporting frames, and an adjusting assembly for height adjustment is installed in the bottom plate; the adjusting assembly comprises a bottom groove, an electric push rod and an adjusting slide way, and the electric push rod is arranged in the bottom groove. According to the rehabilitation medical bed for assisting lower limb rehabilitation, through the design of the first connecting side plate, the second connecting side plate and the massage assembly, following type acupoint massage can be conducted according to the exercise condition of the lower limb area, lower limb rehabilitation is assisted, and reinforced massage can be conducted according to the emphasized atrophy position of the lower limb; the massage area can be prolonged according to the length of the lower limbs through the design of the connecting assembly, meanwhile, the massage angle can be adjusted, and in addition, the distance between the two first connecting side plates can be conveniently adjusted through the design of the threaded rod.

The invention belongs to the technical field of medicines, and particularly relates to application of an echinacea caffeic acid derivative to preparation of a medicine or a feed additive for treating animal periodontal diseases and a composition containing the echinacea caffeic acid derivative. The invention discloses application of an echinacea caffeic acid derivative in preparation of a medicine for treating animal periodontal diseases. Experiments prove that the echinacea caffeic acid derivative has the effects of improving feline gingivitis, gingival bleeding, gingival atrophy, alveolar bone loss and the like, can be used for treating and preventing animal periodontal diseases, and has smaller toxic and side effects while ensuring that a better periodontal disease treatment effect can be realized.

There remains a need for effective therapeutic agents for the treatment of TGFβ superfamily-associated disorders. [Solution] Polypeptides comprising an activin receptor type IIB (ActRIIB) ectodomain (ECD) variant are provided. In some embodiments, the polypeptides of the present disclosure comprise an ActRIIB-ECD variant fused to an Fc domain portion. The present disclosure also provides pharmaceutical compositions and methods using the polypeptides to treat diseases and conditions associated with TGF-β superfamily ligand signaling, such as metabolic disorders, diabetes, obesity, cardiometabolic disease, pulmonary hypertension, fibrosis, muscle weakness and atrophy, bone damage, and / or low red blood cell levels (e.g., anemia).

This invention discloses an injection method for CaHA microsphere products that enhance facial three-dimensionality through multi-layering, relating to the field of cosmetic technology. The method includes: precise injection techniques and area division based on specific needs; and a combination of needle angle, injection depth, layer, and dosage for specific anatomical locations. Specifically designed for Asian facial structures, it provides a strong, naturally integrated solution. By using CaHA microsphere injection products, the following effects can be achieved: Facial volume replenishment: effectively replenishing facial soft tissue atrophy and fat loss caused by aging, skin aging, or genetic factors, restoring facial fullness. It is commonly used to fill sunken areas of the face, such as tear troughs, nasolabial folds, sunken temples, and sunken cheeks.

The present invention addresses the problem of providing an inhibitor for retinochoroidal disorders, in particular, an inhibitor for retinochoroidal scar formation and retinochoroidal atrophy in an epiretinal, intraretinal or subretinal tissue. This problem can be solved by preparing an inhibitor for retinochoroidal disorders which comprises, as an active ingredient, (E)-4-(2-{3-[(1H-pyrazol-1-yl)methyl]-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-yl}vinyl)benzoic acid, an ester thereof or a salt of the same. The inhibitor for retinochoroidal disorders can inhibit collagen atrophy of retinal pigment epithelium cells, fibroblasts, glial cells and the like and thus inhibit retinochoroidal disorders.

The invention discloses a new application of Renqingchangjue and an extract of Renqingchangjue. Specifically, the invention provides a new application of Tibetan medicine Renqingchangjue and an extract in preparation of a medicine for treating chronic atrophic gastritis, and systematically clarifies an exact molecular mechanism of the Tibetan medicine Renqingchangjue for treating CAG. The core of the invention is to reveal the core signal axis of Renqingchangjue by inhibiting TNF / NF-kB / Caspase-3 for the first time, so that the Renqingchangjue synergistically exerts the effects of resisting inflammation, resisting apoptosis and promoting mucosa repair, and provides a new intervention target and scientific basis for reversing gastric mucosa gland atrophy. The invention not only provides a modern pharmacological basis for the clinical curative effect of the Renqingchangjue, but also provides a brand new technical scheme and a protection basis for developing a medicine or a medicine composition which is based on the clear pathway target and is used for treating the chronic atrophic gastritis.

The invention discloses application of rehmannia D in preparation of a product for preventing and / or treating myocardial injury, and belongs to the technical field of medicines. The myocardial injury comprises myocardial injury induced by doxorubicin (DOX), and experiments prove that the rehmannia D can obviously improve the heart function decline caused by the DOX; the myocardial cell atrophy induced by DOX can be obviously inhibited; the level of myocardial tissue fibrosis induced by DOX can be obviously inhibited; the DOX-induced myocardial tissue oxidative stress level can be obviously inhibited; in addition, DOX-induced myocardial tissue DNA damage (gamma-H2AX is taken as a marker) can be obviously inhibited. The invention proves that the rehmannia glycoside D can be used as a novel treatment means to be applied to treatment of adriamycin-induced myocardial injury, and the risk of treatment interruption or heart failure due to cardiotoxicity caused by chemotherapy of a patient can be possibly reduced, so that the disease burden of the patient and the pressure of a medical system are relieved.

The present disclosure relates to a method for diagnosing and treating multiple-system atrophy (MSA) in a subject, the method comprising: determining in a subject-derived biological sample an expression level of a gene from the group consisting of: QKI, GGCX, MOCS1, NF1, LINC01572, PRRG3, HMBOX1, PLP1, PPP1CA, C8orf88, TGFB2, MASP1, TIAM1, SYNGAP1, ACTN1, EMP1, NFIL3, GPNMB, PGAM2, ST5, STON1, RFTN1, and MMP14; comparing the subject-derived expression level of the gene with a normal control expression level of the gene obtained from a non-neurodegenerative biological sample; diagnosing the subject as a having MSA by detecting a differential expression of the gene in the subject-derived biological sample as compared to the normal control expression level; and administering a peroxisome proliferator-activated receptor β (PPARβ) agonist or a retinoid X receptor (RXR) agonist to the subject diagnosed as having MSA.

Disclosed are devitalized adipose tissue. Disclosed are compositions comprising devitalized adipose tissue. In some aspects, the compositions further comprise a cryopreservation or lyophilization solution. Disclosed are cryopreserved or lyophilized devitalized adipose tissue. Disclosed are methods of augmenting a soft tissue site of a subject in need thereof comprising administering to the subject a composition comprising devitalized adipose tissue. Disclosed are methods of treating a subject having fat pad atrophy comprising administering to the subject a composition comprising devitalized adipose tissue. Disclosed are methods of treating a subject having lipodystrophy comprising administering to the subject a composition comprising devitalized adipose tissue. Disclosed are methods of treating a subject having a metabolic disease or condition comprising administering to the subject a composition comprising devitalized adipose tissue.

The present invention provides novel irisin peptides (e.g, irisin glycosylation mutants and biologically active fragments thereof). Also provided are methods for preventing or reducing degeneration of dopaminergic neurons and / or preventing or ameliorating at least one motor deficit in a subject in need thereof, such as in a subject with α-synucleinopathy, using the novel irisin peptides to modulate irisin-induced integrin signaling. The novel irisin peptides can also be used in methods for increasing expression of brain-derived neurotrophic factor (BDNF), and / or treating or preventing neurological diseases or disorders that would benefit from decreased neuronal cell death and / or increased neuronal survival in a subject. In addition, the novel irisin peptides may be used in methods for preventing or treating muscular atrophy or muscular dystrophy.

The invention relates to application of a fluorescence value of NEV / OEV in plasma in auxiliary identification of Parkinson's disease and multi-system atrophy. Comprising the following steps that NEVFmax / OEVFmax is used as a diagnostic index for auxiliary identification of PD and MSA, NEVFmax is the maximum value of an NEV reaction endpoint fluorescence signal obtained in an RT-QuIC experiment, and OEVFmax is the maximum value of an OEV reaction endpoint fluorescence signal obtained in the RT-QuIC experiment. Compared with the prior art, the kit has the advantages that the PD and the MSA are identified by combining the peripheral blood with the alpha-syn amplification technology for the first time, efficient identification of the PD and the MSA is realized, and the blank of identifying the two diseases by combining the exosome in the peripheral blood with the alpha-syn amplification technology is filled.

The invention features polypeptides that include an extracellular ActRII chimera. In some embodiments, a polypeptide of the invention includes an extracellular ActRII chimera fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, bone damage, low red blood cell levels (e.g., anemia or blood loss), low platelet levels (e.g., thrombocytopenia), low neutrophil levels (e.g., neutropenia), fibrosis, metabolic disorders, and / or pulmonary hypertension.